Last reviewed · How we verify
STRONTIUM CHLORIDE
At a glance
| Generic name | STRONTIUM CHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1993 |
Approved indications
Common side effects
Key clinical trials
- TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus (PHASE2)
- Successful Pregnancy and Delivery After AOA (NA)
- Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer (PHASE3)
- Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases (PHASE4)
- The Strontium Chloride Associated With Photobiomodulation in the Control of Post-bleaching Sensitivity (NA)
- Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases (PHASE2)
- Novel Approach With Double Agent Artificial Oocyte Activation for Repeated Fertilization Failure Due to Combined Sperm and Oocyte Factor (NA)
- Artificial Oocyte Activation Comparing Tow Different Agents (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STRONTIUM CHLORIDE CI brief — competitive landscape report
- STRONTIUM CHLORIDE updates RSS · CI watch RSS